EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Viva Biotech Holdings's enterprise value is HK$2,303 Mil.
Viva Biotech Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$363 Mil. Therefore, Viva Biotech Holdings's EV-to-EBITDA for today is 6.35.
The historical rank and industry rank for Viva Biotech Holdings's EV-to-EBITDA or its related term are showing as below:
HKSE:01873'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -68.34 Med: 6.54 Max: 56.75
Current: 6.35
During the past 8 years, the highest EV-to-EBITDA of Viva Biotech Holdings was 56.75. The lowest was -68.34. And the median was 6.54.
HKSE:01873's EV-to-EBITDA is ranked better than 56.79% of 449
companies
in the Biotechnology industry
Industry Median: 9.2
vs HKSE:01873: 6.35
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Viva Biotech Holdings EV-to-EBITDA Historical Data
The historical data trend for Viva Biotech Holdings's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Viva Biotech Holdings's EV-to-EBITDA
For the Biotechnology subindustry, Viva Biotech Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viva Biotech Holdings's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viva Biotech Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Viva Biotech Holdings's EV-to-EBITDA falls into.
Viva Biotech Holdings's current Enterprise Value is HK$2,303 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Viva Biotech Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$363 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Viva Biotech Holdings's PE Ratio for today is calculated as:
Viva Biotech Holdings's share price for today is HK$0.62.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Viva Biotech Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.153.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Viva Biotech Holdings's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Viva Biotech Holdings (HKSE:01873) Business Description
Viva Biotech Holdings is an integrated drug discovery platform. The company's operating segment includes Drug discovery services and Contract Development Manufacture Organisation (CDMO) and commercialisation services. It generates maximum revenue from the Contract Development Manufacture Organisation (CDMO) and commercialisation services segment. The Contract Development Manufacture Organisation ("CDMO") and commercialisation services segment includes contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:01873 has been successfully added to your 